Cell Rejuvenation Research
Research program focused on translating cell rejuvenation science into future medicines.
Explore Cell Rejuvenation ResearchHealth & Frontier Tech / COMPANY INTELLIGENCE
Altos Labs
Researches cellular rejuvenation and approaches to reversing disease-related cell damage.
01 / THE BUSINESS
How Altos Labs creates value.
Researches cellular rejuvenation and approaches to reversing disease-related cell damage. The research focus is whether customer adoption can support attractive economics after development, delivery and ongoing service costs.
SectorHealth & Frontier Tech
Founder coverage1 profile
Research checkedSep 18, 2026
EXPLORE THE BUSINESS FIRSTHAND
Products, platforms & programs.
Explore what Altos Labs builds through its official product and program pages.
Official product and program links; no affiliate commissions are attached to these links. Availability and eligibility are determined by the company. Research programs are not necessarily commercially available products.
02 / PEOPLE BEHIND THE COMPANY
Meet the builders.
Co-founder
Rick Klausner
Rick Klausner is a co-founder of Altos Labs. The company’s founding and leadership material provides context for its work in cellular rejuvenation.
Explore founderSelected founders; historical founding roles are distinct from current management positions.
03 / CAPITAL & OWNERSHIP
Follow the financing.
Selected disclosed events, newest first. Announcement values describe that transaction and date; they are not current share prices. Debt, equity and secondary transactions are identified separately.
A financing figure is not established here.
Use the original company sources below to check new announcements. We have not substituted an estimate for a disclosed round.
04 / IN THEIR OWN WORDS
Watch. Listen. Form your view.
A direct interview has not yet been verified for this profile. The company’s official materials are linked below.
Interviews reflect the speaker’s perspective at publication. Company statements are not independent verification.
05 / EDITORIAL ANALYSIS
The opportunity. The open questions.
Our interpretation of the business model and cited sources, not a valuation or a recommendation.
The case to investigate
- Scientific validation of cellular programming and translation into human therapies.
- A stronger product position becomes economically meaningful when customers renew, expand and pay enough to cover delivery costs.
Pressure-test the thesis
- Very early science.
- Long clinical timelines.
- Uncertain commercial pathways.
What to watch next
01
Peer-reviewed findings — what changed in the latest original disclosure?
02
Clinical pipeline formation — what changed in the latest original disclosure?
03
Research talent — what changed in the latest original disclosure?
THE RIGHT CONVERSATION STARTS HERE
Find help for the financial decisions ahead.
Start with your priorities, explore relevant profiles, and tell us whether you’d like help arranging a conversation.
Find your match Ask our team to follow up ↗You choose how to be contacted. No obligation.
YOUR RESEARCH WORKSPACE
Keep the questions that matter.
Use this checklist to record what you have investigated. Your notes stay in this browser.
06 / RESEARCH TRAIL
Go straight to the source.
Research checked Sep 18, 2026. Selected public disclosures, not a complete capitalization table or securities-filing search. Missing information is left unconfirmed. No investment availability or IPO date is implied.